Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated
June 28, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Reports additional ZN-c3 Phase 1 interim monotherapy data, demonstrating increased tumor reduction and durability in the exceptional responder population, as well as newly confirmed responses and an...
Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference
May 28, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
May 17, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily pre-treated...
Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor
April 12, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
April 10, 2021 13:30 ET
|
ZENTALIS PHARMACEUTICALS
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for...
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
March 25, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5 Announced strategic collaboration with Tempus to expand and strengthen...
Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021
March 10, 2021 16:30 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
February 25, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced a strategic collaboration with Tempus to leverage the company’s...
Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
February 24, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
February 10, 2021 07:00 ET
|
ZENTALIS PHARMACEUTICALS
NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small...